Dr. Jeff Trickett is a neuroscientist, biotech strategist, and author. He hosts Innovating Tomorrow’s Medicine, a podcast highlighting the people and ideas reshaping the future of healthcare. He created the show to go beyond the headlines with honest conversations from biotech founders, researchers, clinicians and investors who are turning bold ideas into real-world impact. His goal is to discover the strategies they use, the insights behind their success and breakthroughs that will define the future of medicine; while challenging the way we think about health, science, and progress.
Innovating Tomorrow's Medicine
Claim This Podcastby Jeff Trickett
5.0(6 reviews)
17 episodes
Updated Daily
Accepts GuestsHas Sponsors
Podcast Overview
Dr. Jeff Trickett is a neuroscientist, biotech strategist, and author. He hosts Innovating Tomorrow’s Medicine, a podcast highlighting the people and ideas reshaping the future of healthcare. He created the show to go beyond the headlines with honest conversations from biotech founders, researchers, clinicians and investors who are turning bold ideas into real-world impact. His goal is to discover the strategies they use, the insights behind their success and breakthroughs that will define the future of medicine; while challenging the way we think about health, science, and progress.
Language
🇺🇲
Publishing Since
7/31/2025
1 verified contact email on file for Innovating Tomorrow's Medicine
Pitch yourself as a guest, propose sponsorships, or reach out directly to the host.
Recent Episodes
January 7, 2026
Sneak Peek: Targeting mRNA with Small Molecules: David Weitz, Syrna Therapeutics
<p>What if we could stop disease-causing proteins before they're even made—using small molecules to target their mRNA?</p><p>David Weitz, CEO of Syrna Therapeutics, is pioneering exactly that: 3D structure-guided drug discovery for mRNA, coupled with covalent translation inhibitors that silence proteins at the source.</p><p>🎙️ Full episode drops 7 January 2026</p><p>In the complete interview, we dive into:</p><p>• Why mRNA is an untapped drug target</p><p>• 3D structure-guided discovery and covalent inhibitors</p><p>• Lead programs in immunology and neurodegeneration</p><p>• Building Syrna and coming out of stealth</p><p>Subscribe so you don't miss it.</p><p>#SneakPeek #mRNA #DrugDiscovery #Biotech</p>
January 7, 2026
Targeting mRNA with Small Molecules: David Weitz, Syrna Therapeutics
<p>What if we could silence disease-causing proteins not by targeting the protein itself, but by preventing its mRNA from ever being translated—using small-molecule drugs?</p><p>In this episode, David Weitz, Co-founder, President and CEO of Syrna Therapeutics, shares how his company is pioneering a revolutionary approach: 3D structure-guided drug discovery for mRNA, coupled with covalent translation inhibitors that block disease-causing proteins before they're even made.</p><p>What we discuss:</p><p>• Why mRNA represents an untapped class of small-molecule drug targets</p><p>• How covalent translation inhibitors work to silence protein expression</p><p>• 3D structure-guided drug discovery: revealing druggable domains in mRNA</p><p>• Lead programs in immunology and neurodegeneration</p><p>• The universal mechanism that can be applied to any mRNA with a druggable structured domain</p><p>• Coming out of stealth: building Syrna and attracting top-tier investors</p><p>• Personal reflections on pioneering a fundamentally new drug discovery approach</p><p>This isn't traditional RNA therapeutics. This is small-molecule drug discovery targeting mRNA—a completely new frontier in precision medicine.</p><p>About the Guest: David Weitz is Co-founder, President and CEO of Syrna Therapeutics, a biotechnology company pioneering 3D structure-guided drug discovery for mRNA targets using covalent translation inhibitors.</p><p>About the Show: Innovating Tomorrow's Medicine features conversations with biotech leaders, researchers, and innovators who are transforming bold ideas into real-world impact in healthcare and life sciences.</p><p>🔗 Connect:</p><p>• Syrna Therapeutics: [https://www.syrnatx.com/]</p><p>• David Weitz: [https://linkedin.com/in/david-weitz-25ba]</p><p>• Host Jeff Trickett: [https://www.linkedin.com/in/jeff-trickett]</p><p>📧 Questions or guest suggestions? [jeffreytrickett@gmail.com]</p><p>#Biotech #mRNA #DrugDiscovery #SmallMolecule #Immunology #Neurodegeneration #PrecisionMedicine #Innovation #RNATherapeutics</p>
December 19, 2025
Predicting Patient Response Before Trials Start: Pilgrim Jackson, Yatiri Bio
<p>What if you could know before a clinical trial which patients will respond? Not after Phase 2 fails. Not after spending $50M. Before you even start.</p><p>In this episode, Pilgrim Jackson, CEO of Yatiri Bio, shares how his company is using proteomics to predict treatment response in AML and ovarian cancer with 100% accuracy so far.</p><p>What we discuss:</p><p>• How proteomic signatures differentiate responders from non-responders in AML and ovarian cancer</p><p>• Why this could reduce Phase 2 trial enrollment from 100 patients to 40—cutting costs in half</p><p>• De-risking clinical trial design and addressing patient heterogeneity</p><p>• Regulatory considerations for biomarker-driven and stratified trials</p><p>• The future of precision oncology and patient-centric trial design</p><p>This isn't incremental improvement. This is a completely different way to run trials.</p><p>About the Guest: Pilgrim Jackson is CEO of Yatiri Bio, a biotechnology company decoding proteins to predict treatment response in oncology.</p><p>About the Show: Innovating Tomorrow's Medicine features conversations with biotech leaders, researchers, and innovators who are transforming bold ideas into real-world impact in healthcare and life sciences.</p><p>🔗 Connect:</p><p>• Yatiri Bio: [https://yatiribio.com]</p><p>• Pilgrim Jackson:[https://www.linkedin.com/in/pilgrimjackson]</p><p>• Host Jeff Trickett: [https://www.linkedin.com/in/jeff-trickett]</p><p>📧 Questions or guest suggestions? [jeffreytrickett@gmail.com]</p><p>#Biotech #ClinicalTrials #PrecisionMedicine #Proteomics #Oncology #AML #DrugDevelopment</p>
17 total episodes available
Deep-dive analytics for Innovating Tomorrow's Medicine
Frequently asked questions
Have a different question and can't find the answer you're looking for? Reach out to our support team by sending us an email and we'll get back to you as soon as we can.
- What is Innovating Tomorrow's Medicine?
- How often does this podcast release new episodes?
This podcast updates daily.
- Where can I listen to this podcast?
This podcast is available on 4 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.
- Does this podcast accept guests?
Yes, this podcast regularly features guests.
Legal Disclaimer
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at hey@podengine.ai for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.